<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389727</url>
  </required_header>
  <id_info>
    <org_study_id>2004-01avr-074</org_study_id>
    <nct_id>NCT00389727</nct_id>
  </id_info>
  <brief_title>Simultaneous Integrated Boost (SIB)- IMRT</brief_title>
  <official_title>A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the feasibility of increasing dose of irradiation
      with IMRT using a SIB approach over 6 weeks.

      The primary endpoint of the study will be acute toxicity assessed during treatment and during
      the first 3 months following the completion of radiotherapy The secondary endpoint will
      include loco-regional control, disease-free survival, survival and late toxicity at 2 years
      after completion of radiotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Loco-regional failures remain a major concern following irradiation of locally advanced head
      and neck cancers. This has led radiation oncologists to investigate novel approaches offering
      better therapeutic indexes. Modification of dose fractionation schedules can improve the
      therapeutic outcome by using accelerated or hyperfractionated regimes -Ang, 1990; Ang, 1998;
      Fu, 2000; Gwozdz, 1997-. Intensity Modulated Radiation Therapy (IMRT) technique allows the
      planning and irradiation of different targets at different dose levels in a single treatment
      session, instead of successive treatment plans. With conventional 2D radiotherapy, both
      normal tissues and tumors are irradiated with a similar dose per fraction of 1.8-2 Gy,
      whereas with IMRT dose gradients are introduced in such a manner that normal tissues receive
      a much lower dose per fraction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2004</start_date>
  <completion_date type="Actual">May 26, 2008</completion_date>
  <primary_completion_date type="Actual">May 26, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>during treatment and during the first 3 months following the completion of radiotherapy</time_frame>
    <description>acute toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite endpoint</measure>
    <time_frame>from ratiotherapy until 2 years after completion of radiotherapy</time_frame>
    <description>composite including loco-regional control, disease-free survival, survival and late toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>Group 1 Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Group 1 Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients with squamous cell carcinoma of the oropharynx, hypopharynx and larynx

          -  Stage T2-N0-M0, T2-N1-M0 or T3-N0-M0

          -  World Health Organization (WHO) Performance Status of 0 or 1 or Karnofsky performance
             status ≥ 70.

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Second primary tumor at the time of diagnosis

          -  Previous history of malignant tumor in the last five years except basal cell carcinoma
             and carcinoma in situ of the cervix

          -  Previous treatment with surgery, radiotherapy or chemotherapy for head and neck
             malignancy

          -  Any evidence of severe or uncontrolled systemic diseases (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic or renal disease), or psychological
             disorder

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Gregoire, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques universitaires Saint Luc Brussels Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Maingon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre George-François Leclerc Dijon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Nuyts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Gasthuisberg, Katholiek universiteit van Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Calais, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Tours, Bretonneau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine Serre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>centre Val d'Aurelle, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

